Cannabis Learning EDU
Statistics on Parkinson's Disease:
More than 10 million people worldwide are living with Parkinson’s disease.
Approximately 60,000 Americans are diagnosed with PD each year..
By 2020, an estimated 930,000 people in the US will be diagnosed with PD.
(Source: Parkinson’s Foundation, www.parkinson.org)
US Patent 6630507 B1, Oct 7, 2003 - Cannabinoids as Antioxidants and Neuroprotectants
Study: Inhaled Cannabis Mitigates Parkinson’s Disease Symptoms
NORML. 2014 Mar 17, online article.
Smoking Pot Eases Tremors in Parkinson’s
Medpage Today. 2013 Jun 18, online article.
Parkinson’s Helped By Marijuana-Like Chemicals in Brain
Medical News Today. 2007 Feb 11, online article.
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease
Di Marzo, Vincenzo, et al.
The Journal of the Federation of American Societies for Experimental Biology. 2000 July, 14(10): 1432-1438 (Full).
Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkison disease: an open-label observational study
Lotan, Treves Ta, et al.
Clinical Neuropharmacology. 2014 Mar, 37(2): 41-44 (abstract).
Cannabinoids and Parkinson’s Disease
Garcia-Arencibia, Moises, et al.
CNS & Neurological Disorders - Drug Targets. 2009 Dec, 8(6): 432-439 (abstract).
Cannabidiol for the treatment of psychosis in Parkinson’s disease
Zuardi, AW, et al.
Journal of Psychopharmacology. 2008 Sep 18, online article (abstract).
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson’s disease
Lastres-Becker, Isabel, et al.
Neurobiology of Disease. 2005 Jul, 19(1-2): 96-107 (abstract).
Therapeutic Potential of Cannabinoids in CNS Disease
Ludovic, Dr J Croxford, et al.
CNS Drugs. 2003 Mar, 17(3): 179-202 (abstract).
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson’s disease
Fox, Susan H., et al.
Movement Disorders. 2002 Dec, 17(6): 1180-1187 (abstract).
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study
Sieradzan, K.A., et al.
Neurology. 2001 Dec 11, 57(11): 2108-2111 (abstract).
Neuroprotection by delta9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo Excitotoxicity
van der Stelt, M., et al.
The Journal of Neuroscience. 2001 Sep 1, 21(17): 6475-6479 (abstract).
The role of Cannabinoids in neurodegenerative diseases
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2001 May, 25(4): 743-765 (abstract).
Role of the endogenous cannabinoid system as a modulator of dopamine transmission: Implications for Parkinson’s disease and schizophrenia
Rodriguez de Fonseca, Fernando, et al.
Neurotoxicity Research. 2001 Jan, 3(1): 23-35 (abstract).
Cannabis in Movement Disorders
Muller-Vahl, K.R., et al.
Research in Complementary Medicine. 1999 Oct, 6: 23-27 (abstract).